Detalhe da pesquisa
1.
Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor.
Blood
; 142(1): 62-72, 2023 07 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36796019
2.
Emergence and Targeting of Acquired and Hereditary Resistance to Multikinase RET Inhibition in Patients With RET-Altered Cancer.
JCO Precis Oncol
; 32019.
Artigo
em Inglês
| MEDLINE | ID: mdl-32923848